Sign in

Bill Kirk

Managing Director and Senior Research Analyst at Roth Capital Partners, LLC

Bill Kirk is a Managing Director and Senior Research Analyst at Roth Capital Partners, LLC, specializing in the coverage of the Beverage, Food Retail, and Cannabis sectors. He follows over 40 publicly traded companies including Target, United Natural Foods (UNFI), Walmart, and other major retailers, with a performance track record highlighted by a most profitable rating generating a 235.90% return on UNFI. Since joining Roth Capital in February 2023, Bill has brought more than 15 years of fundamental research and valuation experience from previous roles at RBC Capital Markets, UBS, and Duff & Phelps. Holding the CFA designation and registered industry credentials, Kirk is recognized for his technical expertise and breadth of market analysis despite a TipRanks analyst success rate of approximately 41% and an average return per rating of -7.5%.

Bill Kirk's questions to HF Foods Group (HFFG) leadership

Bill Kirk's questions to HF Foods Group (HFFG) leadership • Q2 2025

Question

Inquired about the impact of lower consumer foot traffic on the Asian specialty food segment and HF Foods' market share, and also asked about the prioritization and funding of the company's strategic growth projects, including M&A.

Answer

The CEO explained that lower foot traffic is specific to certain markets and restaurant types (buffets) due to immigration policy changes, rather than a broader industry trend. Regarding growth, the company is pursuing a dual strategy of organic expansion through facility investments (funded by cash flow) to unlock cross-selling opportunities, and tuck-in M&A, with larger deals potentially requiring different capital structures.

Ask Fintool Equity Research AI

Bill Kirk's questions to HF Foods Group (HFFG) leadership • Q2 2025

Question

Bill Kirk of Roth Capital Partners, LLC inquired about the performance of the Asian Specialty food service subsegment amid lower consumer foot traffic and asked about HF Foods' current market share. He also questioned the prioritization of strategic growth projects, including M&A, and how these initiatives would be funded.

Answer

CEO Felix Lin explained that the lower foot traffic was market-specific, primarily affecting buffet restaurants in regions with a heavy agricultural presence due to shifts in immigration policy, rather than broader industry trends. Regarding growth, Lin outlined a dual strategy: organic growth through capacity expansion in Charlotte and Atlanta to unlock a potential $200-$300 million in cross-selling, and tuck-in M&A targeting first-generation operators. He stated that most projects can be funded by cash flow, but larger M&A might require exploring different capital structures.

Ask Fintool Equity Research AI

Bill Kirk's questions to Canopy Growth (CGC) leadership

Bill Kirk's questions to Canopy Growth (CGC) leadership • Q1 2026

Question

Bill Kirk of Roth Capital Partners, LLC asked what specific momentum Canopy Growth is seeing that suggests prospects for U.S. cannabis rescheduling are improving.

Answer

CEO Luc Mongeau declined to comment directly on rescheduling prospects but stated that the company sees momentum in select U.S. geographies where demand is increasing and infrastructure is being built for profitable operations, even ahead of federal changes. He expressed confidence in the work being done by Canopy USA to position itself for future opportunities.

Ask Fintool Equity Research AI

Bill Kirk's questions to INNOVATIVE INDUSTRIAL PROPERTIES (IIPR) leadership

Bill Kirk's questions to INNOVATIVE INDUSTRIAL PROPERTIES (IIPR) leadership • Q2 2025

Question

Bill Kirk questioned the opportunity cost of the $270 million IQHQ investment, suggesting that at the stock's current dividend yield, share buybacks could offer a better return than the 14% yield from the IQHQ deal. He also asked about the flexibility regarding the timing and size of the preferred stock funding.

Answer

Executive Chairman Alan Gold responded that the company does not base its strategy on daily stock market volatility and that the investment is highly accretive relative to their overall cost of capital and cash on hand. CFO David Smith added that the deal provides flexibility in funding through Q2 2027 and is expected to improve IIP's overall access to capital markets by diversifying into the established life science sector.

Ask Fintool Equity Research AI

Bill Kirk's questions to INNOVATIVE INDUSTRIAL PROPERTIES (IIPR) leadership • Q2 2025

Question

Bill Kirk from Roth Capital Partners, LLC questioned the opportunity cost of the IQHQ investment, suggesting share buybacks could yield a better return than the deal's 14% yield, given the stock's current dividend yield. He also asked about the flexibility in timing and commitment for the preferred stock portion of the investment.

Answer

Executive Chairman Alan Gold responded that the stock's high yield was a recent fluctuation and the decision was based on the overall cost of capital, making the 14% return on previously low-earning cash highly accretive. He affirmed there is significant flexibility in funding the investment over time. CFO David Smith added that diversifying into the established life science sector is expected to improve IIP's overall access to capital markets.

Ask Fintool Equity Research AI

Bill Kirk's questions to INNOVATIVE INDUSTRIAL PROPERTIES (IIPR) leadership • Q2 2025

Question

Bill Kirk from Roth Capital Partners, LLC questioned the opportunity cost of the 14% yielding IQHQ investment versus buying back IIPR stock, which had a dividend yield above 16%, and asked about the funding flexibility.

Answer

Executive Chairman Alan Gold responded that decisions are based on overall cost of capital, not daily stock volatility, and that deploying cash earning 3-4% into a 14% yielding investment is highly accretive. CFO David Smith added that the funding occurs over time until Q2 2027 and that diversifying into the life science sector should improve IIPR's overall access to capital markets.

Ask Fintool Equity Research AI

Bill Kirk's questions to AURORA CANNABIS (ACB) leadership

Bill Kirk's questions to AURORA CANNABIS (ACB) leadership • Q1 2026

Question

Bill Kirk from Roth Capital Partners, LLC asked for clarification on the Vivo liabilities moving to current on the balance sheet and sought directional guidance for Q2 adjusted EBITDA.

Answer

CFO Simona King clarified that the liability shift was a required accounting treatment due to a covenant issue at Vivo, which is being resolved and does not impact Aurora's audit. CEO Miguel Martin added that they expect a quick resolution. For Q2 guidance, King stated that the company expects adjusted EBITDA to remain positive and to grow compared to the current quarter's result.

Ask Fintool Equity Research AI

Bill Kirk's questions to Grocery Outlet Holding (GO) leadership

Bill Kirk's questions to Grocery Outlet Holding (GO) leadership • Q2 2025

Question

Bill Kirk from Roth Capital Partners, LLC asked if the company was considering allowing more scale at the Independent Operator (IO) level, such as multi-store ownership, and inquired about the quantified impact of the Easter holiday shift.

Answer

President and CEO Jason Potter confirmed that the company has continued its practice of allowing its most competent and successful IOs to take on additional stores, noting some were added this quarter. Regarding the Easter shift, Potter referred back to the previous quarter's discussion, stating that the impact was recognized and that the Q2 reported comp of 1.1% was in line with the guidance provided.

Ask Fintool Equity Research AI

Bill Kirk's questions to MOLSON COORS BEVERAGE (TAP) leadership

Bill Kirk's questions to MOLSON COORS BEVERAGE (TAP) leadership • Q2 2025

Question

Bill Kirk from ROTH Capital Partners, LLC questioned why the company's stock price doesn't reflect its improved market share and EPS since 2019, asking if a strategic change is needed. He also asked why pricing is limited to 1-2% when COGS are rising more significantly.

Answer

President and CEO Gavin Hattersley responded that the company views its stock as an attractive investment, evidenced by its aggressive share repurchase program. On pricing, he explained that their strategy is not based solely on input costs but on a sophisticated, market-by-market revenue management program that considers brand health and consumer receptivity.

Ask Fintool Equity Research AI

Bill Kirk's questions to Tilray Brands (TLRY) leadership

Bill Kirk's questions to Tilray Brands (TLRY) leadership • Q4 2025

Question

Nik, on behalf of Bill Kirk from Roth Capital Partners, asked about the potential for proposed German legislation to inhibit telemedicine and whether Tilray is becoming more bullish on the U.S. cannabis reform opportunity.

Answer

Chief Strategy Officer Denise Faltischek addressed the German issue, clarifying it is only a proposal and that Tilray is actively working with industry groups to prevent changes that could push patients to the illicit market. CEO & Chairman Irwin Simon added that he expects significant pushback. On U.S. reform, Simon expressed cautious optimism, calling the new DEA appointment a 'good step' but reiterating that the company is diversified to succeed regardless of the outcome.

Ask Fintool Equity Research AI

Bill Kirk's questions to Tilray Brands (TLRY) leadership • Q1 2025

Question

Bill Kirk of Roth MKM sought confirmation of the fiscal 2025 revenue guidance of $950 million to $1 billion and asked if the recent Molson Coors brand acquisition was the M&A contemplated in that guidance. He also questioned what factors were offsetting positive developments in the international business, given its relatively flat quarterly revenue.

Answer

CEO Irwin Simon confirmed the fiscal 2025 revenue guidance remains $950 million to $1 billion and clarified that it does not yet include the impact of the Molson Coors acquisition. Chief Strategy Officer Denise Faltischek and Simon explained that international revenue was impacted by the strategic discontinuation of sizable but unprofitable sales to Israel, which has been offset by entry into new, more profitable markets like Poland and the U.K.

Ask Fintool Equity Research AI

Bill Kirk's questions to BOSTON BEER CO (SAM) leadership

Bill Kirk's questions to BOSTON BEER CO (SAM) leadership • Q2 2025

Question

Bill Kirk asked if negative earnings were a real possibility for the second half of the year based on the guidance, and also inquired about the company's plans for D9 THC products and observations on competitive trade practices in that space.

Answer

CFO Diego Reynoso confirmed that negative earnings are a possibility, particularly in the seasonally slow fourth quarter, depending on summer depletion trends. Founder & Chairman C. James Koch addressed D9 THC, stating that despite experience in Canada, the extreme political and regulatory volatility in the U.S. makes it too risky to enter at this time. He added he has not seen D9 competitors engaging in large-scale slotting fee practices.

Ask Fintool Equity Research AI

Bill Kirk's questions to UNITED NATURAL FOODS (UNFI) leadership

Bill Kirk's questions to UNITED NATURAL FOODS (UNFI) leadership • Q3 2025

Question

Bill Kirk of Roth Capital Partners, LLC asked for clarification on whether UNFI's non-GAAP guidance was being reiterated or simply not updated, and questioned the strategic rationale behind ending the distribution agreement with Key Food.

Answer

CEO Sandy Douglas provided context on the ongoing IT security incident, after which President & CFO Giorgio Matteo Tarditi confirmed that guidance was left unchanged due to the incident's uncertainty, despite performance that would have otherwise warranted a raise. Douglas explained the Key Food exit was a mutual decision to leave an unprofitable relationship, driven by post-COVID operational factors. Tarditi added that the net cash impact would be offset by working capital release and expense reduction, with a payback period under one year.

Ask Fintool Equity Research AI